10.02.2015 • News

DuPont and Chenguang Link on Fluoroelastomers

DuPont Fluoropolymer Solutions and Zhonghao Chenguang Chemical Research Institute (Chenguang), a subsidiary of China National Chemical Corporation (ChemChina), have formed a 50:50 joint venture for production and marketing of fluoroelastomer gums and pre-compounds in China.

Combining the two companies' expertise to launch new products, improve technology and optimize capacity toward guaranteeing a reliable supply of high-quality fluoroelastomers for markets and customers is the focus of the cooperation.

Both companies have strategic positions in the fluoroelastomers industry and are evaluating additional potential areas for strategic collaboration.

The joint venture, to be named DuPont Haohua Chenguang Fluoromaterials (Shanghai) Co. Ltd, will sell fluoroelastomers under the Chenguang and Viton brands, leveraging the DuPont technology leadership and the Chenguang integrated technology and manufacturing footprint. The jv also will invest in a new pre-compound manufacturing facility in Shanghai.

Thierry F. J. Vanlancker, president of DuPont Chemicals & Fluoroproducts, said the new company is " ideally positioned to support China's growing market for fluoroelastomers, particularly for high-performance applications in China's expanding automotive, aerospace, energy, electronics and telecommunications markets."

Robert Lu, vice president, China National Chemical Corporation said the cooperation will create a new entity that can more effectively serve customers in China and globally through new technologies and specialty fluoroelastomers.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.